eligibility_summary
Adults ≥18 with measurable epithelial ovarian/fallopian tube/primary peritoneal/carcinosarcoma, platinum-pretreated/resistant (BRCA: prior PARP), MUC1+ tumor, ECOG 0–1, expected survival 6–24 mo, adequate marrow/organ function, O2 ≥90%, negative pregnancy, willing for consent, samples, leukapheresis, follow-up at Mayo AZ. Exclude active CNS mets, prior anti-MUC1, PCL, pregnancy/nursing, recent MI/CHF, unresolved ≥G2 tox, uncontrolled illness, HIV on ART, high-dose steroids, other trials, recent other cancers, active autoimmune disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06483048 (Phase 1, single-arm, dose-escalation): Autologous MUC1-activated T cells (adoptive cellular immunotherapy). Product: PBMC-derived T cells expanded/activated ex vivo to recognize MUC1, infused IV on day 0 ± day 21. Mechanism: TCR-mediated, MHC-restricted recognition of MUC1 on tumor cells, inducing T-cell activation, cytotoxic killing, and cytokine release, persistence/TCR clonality assessed. Preconditioning: cyclophosphamide or bendamustine (alkylating chemotherapies) for lymphodepletion to reduce host lymphocytes/Tregs and promote engraftment/expansion. Targets: MUC1-expressing epithelial ovarian/fallopian tube/primary peritoneal carcinoma cells. Pathways/cells: tumor-surface MUC1 antigen, CD3+ T-cell effector functions (IFN-γ, cytotoxic molecules), systemic cytokine dynamics. Safety focus includes CRS and ICANS.